The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
about
New and emerging disease modifying therapies for multiple sclerosisAlemtuzumab for multiple sclerosisAlemtuzumab for multiple sclerosisExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisOptimizing treatment success in multiple sclerosisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsAlemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewAlemtuzumab for Multiple Sclerosis.Multiple sclerosis--new treatment modalitiesAlemtuzumab in the treatment of multiple sclerosis: patient selection and special considerationsAlemtuzumab for the treatment of multiple sclerosisComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosisRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisSecondary autoimmune diseases following alemtuzumab therapy for multiple sclerosisThe immunopathology of multiple sclerosis: an overviewBiomarkers of treatment response in multiple sclerosisThe expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosisSound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Primary progressive multiple sclerosis: progress and challenges.First use of alemtuzumab in Balo's concentric sclerosis: a case report.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Diffusion tensor MRI as a biomarker in axonal and myelin damage.The role of MRI in the evaluation of secondary progressive multiple sclerosis.Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwile?Alemtuzumab therapy for multiple sclerosis.Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.Autoimmune T cell responses in the central nervous systemPromising treatments of tomorrow for multiple sclerosis.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.Multiple sclerosis: Pathology, diagnosis and treatments.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisHow implementation of systems biology into clinical trials accelerates understanding of diseases.The role of B cells in solid organ transplantation.Impact of multiple sclerosis relapses on progression diminishes with time
P2860
Q22242305-D9830E7C-171A-4172-ADEC-B481D353546DQ24185899-848E49D2-D63D-450A-9245-E0C5FED4DBDAQ24195076-4DF6CE06-6D3B-4713-8A5C-C11FB4817A96Q26770818-683CDB2D-2E5D-4240-9512-DA4B9B8A242EQ26771968-337B0A50-EFD3-4C42-86C5-569B3BF9A3FCQ26777329-7F6F94B6-4C00-47C1-B8C0-DFEF9C6F0F25Q26800128-19D12258-95BC-4C1E-9D74-06756FF37F26Q26999417-FCDE0831-5738-440C-B9E1-5EC20DB26B41Q28069730-2D767022-A24D-4180-8E7E-A5F6F06C276CQ28072906-7B4C06B3-C788-4227-AAE6-E632DF0FB482Q28077000-C2B2B73E-AE1A-412B-A8BB-E7C19945A03BQ28080506-B198ADB9-BA0E-40C8-A52D-F373A701AEA5Q28081636-7AEC2C5E-7861-40D6-BAEF-8FFB8F0A7AEEQ28087414-220C912C-EF20-40E6-B0E5-DE31737C95E0Q28260587-DC8342CB-1DF8-4485-AFBC-2F5102EA11A1Q28295115-ABA5EFA3-05AA-4B78-9423-FE304AF85B25Q28305094-60333A92-5E8B-4ED2-BC84-1F2BE379812BQ28740407-270870B5-FAA2-4941-B3B0-2D3C4BF70A76Q30432891-BD22A790-958C-4252-B386-EF1A93209EA7Q30458930-F19FE8A7-5E32-445F-9695-5E5B21C83202Q30590258-8F030898-7FD3-4595-9E32-BE50C01C8514Q30657346-5513CBEE-79B6-4C14-A000-0F672EAF6971Q30699740-31CC2C58-CE30-45F0-820B-5C307A61F7E8Q30808014-41857172-7344-4B81-BF8C-A6F8CC084F9EQ30814256-EF66C01B-A678-4AE4-BEB3-976E30B25F95Q31033345-617BE670-7179-40C4-B5F2-6F9DE75B46B1Q33380269-60DC9950-B12D-4498-B283-FF697BD0AE6FQ33404568-36519F96-56B4-4974-A4E4-3C4B5E18E696Q33407411-DA80DE1E-B933-4A5E-8521-9D53E44A67DEQ33412834-E0C049EB-49C4-43C6-933F-F3DC21B01D5DQ33430760-36FD96D2-DE4C-46AE-9987-F937D6DEB15CQ33534161-B9DB296A-A883-4FB5-B526-D6768176C9E4Q33620003-0044E024-28A1-4B13-87C5-798ADB60D67FQ33670947-54F46DFB-8489-4C3A-9DF0-E9F55115CF45Q33736193-C2F6C977-40A3-47B2-909C-11D87E68A0F7Q33745006-A8A44D7B-16C2-48C0-8318-E67B8D7B83B6Q33802186-340298B7-D214-4112-951F-CB4450152441Q33814843-07490A88-D737-4C80-A717-74394CB314D4Q33891696-F8FAE628-554E-41C9-98CF-FC248B93B7EBQ33898204-7ACA1D18-D36B-488C-9CF7-53A81E5258A9
P2860
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@en
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@nl
type
label
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@en
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@nl
prefLabel
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@en
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@nl
P2093
P2860
P1433
P1476
The window of therapeutic oppo ...... m monoclonal antibody therapy.
@en
P2093
Alasdair J Coles
Amanda Cox
D Alastair Compston
David H Miller
Emmanuelle Le Page
Geoff Hale
Jackie Deans
Joanne Jones
S Anand Trip
P2860
P2888
P304
P356
10.1007/S00415-005-0934-5
P577
2005-07-27T00:00:00Z